The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 President’s Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
    • Media
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 President’s Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
    • Media
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
    • Media
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
      • Summit Sponsors
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Master Class 5.0 Trial Academy 2021
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Study Links Depakote with Lower IQ

Posted on February 13, 2013 by Andrew Findley


Lawyersandsettlements.com; February 12, 2013

Atlanta, GA: A new study suggests the use of Depakote while pregnant is linked with having children with a lower IQ. Previous studies suggested that Depakote side effects included an increased risk of so-called Depakote birth defects in children exposed to the anti-seizure medication prior to birth.

The most recent study, published online in The Lancet Neurology (1/23/13), studied 311 children whose IQ was assessed at six years of age. Researchers found that the average IQ among children exposed to valproate (the generic name for Depakote) prior to birth was 97, whereas the average IQ of children exposed to other antiepileptic drugs was 105 or higher.

Researchers found that the effect of valproate on IQ was dose dependent, meaning the higher the dose, the greater the effect on the children’s IQ. Children exposed to less than 1000 mg per day had IQ levels similar to children exposed to other antiepileptic drugs. Among the cognitive abilities tested were verbal ability and memory.

“Children exposed to valproate did poorly on measures of verbal and memory abilities compared with those exposed to the other antiepileptic drugs,” researchers wrote. They concluded, “Fetal valproate exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age.”

“These results build on our earlier work to show that valproate usage during pregnancy has a significant negative effect on children’s IQ, which lasts beyond their earliest years,” said Professor Kimford Meador, lead researcher on the study, in a news release (found online at eurekalert.org; 1/22/13). He further noted that because IQ at age six is strongly related to adult IQ, these test results suggest that valproate use during pregnancy could have long-term adverse effects on a child’s IQ.

The same children were reportedly used in a similar study at three years of age, to determine the effects of valproate on their cognitive abilities. The outcome of that study resulted in the US Food and Drug Administration (FDA) issuing a warning that exposure to valproate prior to birth was associated with impaired cognitive functions. At the time, the FDA noted that the long-term effects of valproate on IQ and cognitive development are not known.

Valproate has also been linked to an increased risk of neural tube birth defects.

http://www.lawyersandsettlements.com/articles/depakote/depakote-lawsuit-side-effects-13-18470.html?utm_expid=3607522-0&utm_referrer=http%3A%2F%2Fwww.lawyersandsettlements.com%2F#.URv4WfXRZfw

Posted in Blog

Comments are closed.

Recent Posts

Sterling Bancorp Agrees to $12.5 Million Settlement with Oklahoma Police Pension & Retirement System

Sterling Bancorp Agrees to $12.5 Million Settlement with Oklahoma Police Pension & Retirement System

April 21st, 2021

Sterling Bancorp Inc. agreed to pay $12.5 million to settle a class-action lawsuit filed by the $3.1 billion Oklahoma Po[Read More...]
Boy Scouts of America and The Hartford Enter $650 Million Settlement for Sex Abuse Claims

Boy Scouts of America and The Hartford Enter $650 Million Settlement for Sex Abuse Claims

April 19th, 2021

After years of legal dispute, The Hartford has entered into a settlement agreement and release with the Boy Scouts [Read More...]
Playland Operator Reaches $12 Million Bankruptcy Settlement

Playland Operator Reaches $12 Million Bankruptcy Settlement

April 19th, 2021

The Westchester County Board of Legislators last week approved a bankruptcy court settlement with Standard Amusements regardi[Read More...]
Santa Fe Agrees To a $36M Settlement With the Firms Responsible For Constructing Its Water Project

Santa Fe Agrees To a $36M Settlement With the Firms Responsible For Constructing Its Water Project

April 9th, 2021

The board of the Santa Fe city and county’s joint Buckman Direct Diversion agreed to a $36 million settlement last wee[Read More...]
Health Net Repaid $97.2M To Settle an Investigation Confirming It Over-Billed the U.S. For Veterans Care

Health Net Repaid $97.2M To Settle an Investigation Confirming It Over-Billed the U.S. For Veterans Care

April 7th, 2021

A Rancho Cordova health insurance company has repaid $97.2 million to settle an investigation into inflated claims submitted [Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.